journal article·2024-01

An elastase-inhibiting, plaque-targeting and neutrophil-hitchhiking liposome against atherosclerosis

Yin Shi, Mei Dong, Yue Wu, Fanglin Gong, Zibin Wang, Lingjing Xue, Zhigui Su

Acta Biomaterialia· Volume 173
Publisher page

Abstract

Neutrophil extracellular traps (NETs) play a crucial role in the formation of vulnerable plaques and the development of atherosclerosis. Alleviating the pathological process of atherosclerosis by efficiently targeting neutrophils and inhibiting the activity of neutrophil elastase to inhibit NETs is relatively unexplored and is considered a novel therapeutic strategy with clinical significance. Sivelestat (SVT) is a second-generation competitive inhibitor of neutrophil elastase with high specificity. However, therapeutic effect of SVT on atherosclerosis is restricted because of the poor half-life and the lack of specific targeting. In this study, we construct a plaque-targeting and neutrophil-hitchhiking liposome (cRGD-SVT-Lipo) to improve the efficacy of SVT in vivo by modifying the cRGD peptide onto SVT loaded liposome, which was based on the interaction between cRGD peptide and integrin ανβ3 on the surface of cells in blood and plaque, including epithelial cell, macrophage and neutrophils. The cRGD-SVT-Lipo could actively tend to or hitchhike neutrophils in situ to reach atherosclerotic plaque, which resulted in enhanced atherosclerotic plaque delivery. The cRGD-SVT-Lipo could also reduce plaque area, stabilize plaque, and ultimately alleviate atherosclerosis progression through efficiently inhibiting the activity of neutrophil elastase in atherosclerotic plaque. Therefore, this study provides a basis and targeting strategy for the treatment of neutrophil-related diseases. STATEMENT OF SIGNIFICANCE: Neutrophil extracellular traps (NETs)-inhibiting is a prospective therapeutic approach for atherosclerosis but has received little attention. The NETs can be inhibited by elastase-restraining. In this work, an intriguing system that delivers Sivelestat (SVT), a predominantly used neutrophil elastase inhibitor with poor targeting capability, is designed to provide the drug with plaque-targeting and neutrophil-hitchhiking capability. The result suggests that this system can effectively hinder the formation of NETs and delay the progression of atherosclerosis.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Neutrophil, Myeloperoxidase and Oxidative Mechanisms · Cell Adhesion Molecules Research · Protease and Inhibitor Mechanisms

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (52)

Show source-provided references
1. Neutrophil extracellular traps kill bacteria10.1126/science.1092385 ↗
2. Neutrophil extracellular traps participate in all different types of thrombotic and haemorrhagic complications of coronary atherosclerosis10.1055/s-0038-1641749 ↗
3. Diabetes primes neutrophils to undergo NETosis, which impairs wound healing10.1038/nm.3887 ↗
4. Albrengues, J.; Shields, M. A. Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. 2018, 361.10.1126/science.aao4227 ↗
5. Neutrophil extracellular traps induce organ damage during experimental and clinical sepsis10.1371/journal.pone.0148142 ↗
6. Presence of luminal neutrophil extracellular traps in atherosclerosis10.1160/TH11-09-0650 ↗
7. Externalized histone H4 orchestrates chronic inflammation by inducing lytic cell death10.1038/s41586-019-1167-6 ↗
8. Nonanticoagulant heparin prevents histone-mediated cytotoxicity in vitro and improves survival in sepsis10.1182/blood-2013-07-514984 ↗
9. High neutrophil numbers in human carotid atherosclerotic plaques are associated with characteristics of rupture-prone lesions10.1161/ATVBAHA.110.209296 ↗
10. Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps10.1083/jcb.201006052 ↗
11. Neutrophil elastase in human atherosclerotic plaques10.1161/01.CIR.0000072792.65250.4A ↗
12. Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis10.1126/science.aaa8064 ↗
13. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus10.1126/scitranslmed.3001201 ↗
14. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA–peptide complexes in systemic lupus erythematosus10.1126/scitranslmed.3001180 ↗
15. Neutrophil elastase, proteinase 3 and cathepsin G: physicochemical properties, activity and physiopathological functions10.1016/j.biochi.2007.10.009 ↗
16. Degradation of native type IV procollagen by human neutrophil elastase. Implications for leukocyte-mediated degradation of basement membranes10.1021/bi00392a025 ↗
17. ONO-5046, a novel inhibitor of human neutrophil elastase10.1016/0006-291X(91)91862-7 ↗
18. Sivelestat reduces inflammatory mediators and preserves neutrophil deformability during simulated extracorporeal circulation10.1016/j.athoracsur.2005.02.038 ↗
19. Inhibition of neutrophil elastase prevents neutrophil extracellular trap formation and rescues mice from endotoxic shock10.1016/j.biomaterials.2020.119836 ↗
20. Neutrophil-based drug delivery systems10.1002/adma.201706245 ↗
21. Chemotaxis-driven delivery of nano-pathogenoids for complete eradication of tumors post-phototherapy10.1038/s41467-020-14963-0 ↗
22. Neutrophil-mediated delivery of therapeutic nanoparticles across blood vessel barrier for treatment of inflammation and infection10.1021/acsnano.5b05583 ↗
23. Nanoparticle-induced neutrophil apoptosis increases survival in sepsis and alleviates neurological damage in stroke10.1126/sciadv.aax7964 ↗
24. αvβ3 integrin expression in normal and atherosclerotic artery10.1161/01.RES.77.6.1129 ↗
25. Integrin signaling in atherosclerosis10.1007/s00018-017-2490-4 ↗
26. Integrin structure, allostery, and bidirectional signaling10.1146/annurev.cellbio.21.090704.151217 ↗
27. Crystal structure of the extracellular segment of integrin αVβ3 in complex with an arg-gly-asp ligand10.1126/science.1069040 ↗
28. Molecular radio afterglow probes for cancer radiodynamic theranostics10.1038/s41563-023-01659-1 ↗
29. Engineered biomimetic nanoreactor for synergistic photodynamic-chemotherapy against hypoxic tumor10.1016/j.jconrel.2022.09.020 ↗
30. AZD9291 resistance reversal activity of a pH-sensitive nanocarrier dual-loaded with chloroquine and FGFR1 inhibitor in NSCLC10.1002/advs.202002922 ↗
31. A single intravenous injection of cyclosporin A–loaded lipid nanocapsules prevents retinopathy of prematurity10.1126/sciadv.abo6638 ↗
32. Integrin-dependent cell adhesion to neutrophil extracellular traps through engagement of fibronectin in neutrophil-like cells10.1371/journal.pone.0171362 ↗
33. Tumor targeting by αvβ3-integrin-specific lipid nanoparticles occurs via phagocyte hitchhiking10.1021/acsnano.9b08693 ↗
34. Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence10.1038/nnano.2017.54 ↗
35. Mouse bone marrow contains large numbers of functionally competent neutrophils10.1189/jlb.0703340 ↗
36. Novel RGD-lipid conjugate-modified liposomes for enhancing siRNA delivery in human retinal pigment epithelial cells10.2147/IJN.S24447 ↗
37. Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones10.1371/journal.pone.0032366 ↗
38. Viable neutrophils release mitochondrial DNA to form neutrophil extracellular traps10.1038/cdd.2009.96 ↗
39. Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice10.1038/s41586-018-0198-8 ↗
40. Biomimetic nanotherapies: red blood cell based core–shell structured nanocomplexes for atherosclerosis management
41. Molecular imaging of the extracellular matrix in the context of atherosclerosis10.1016/j.addr.2016.09.005 ↗
42. Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma
43. A single intravenous injection of cyclosporin A–loaded lipid nanocapsules prevents retinopathy of prematurity10.1126/sciadv.abo6638 ↗
44. PET/CT Imaging of Integrin αvβ3 expression in human carotid atherosclerosis10.1016/j.jcmg.2013.12.003 ↗
45. Endothelial ανβ3 integrin–targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis10.1161/01.ATV.0000235724.11299.76 ↗
46. cRGD enables rapid phagocytosis of liposomal vancomycin for intracellular bacterial clearance10.1016/j.jconrel.2022.02.030 ↗
47. Effect of sivelestat in the treatment of acute lung injury and acute respiratory distress syndrome: a systematic review and meta-analysis10.1007/s44231-023-00032-9 ↗
48. Neutrophil Elastase Inhibitors: a potential prophylactic treatment option for SARS-CoV-2-induced respiratory complications?10.1186/s13054-020-03023-0 ↗
49. Delayed neutrophil elastase inhibition prevents subsequent progression of acute lung injury induced by endotoxin inhalation in hamsters10.1164/ajrccm.161.6.9904047 ↗
50. Clinical Utility of the Sivelestat for the Treatment of ALI/ARDS: moving on in the controversy?10.1007/s44231-022-00012-5 ↗
51. ONO-5046 (Ono Pharmaceutical)
52. Reevaluation of the efficacy and safety of the neutrophil elastase inhibitor, Sivelestat, for the treatment of acute lung injury associated with systemic inflammatory response syndrome; a phase IV study10.1016/j.pupt.2011.03.001 ↗